Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sarah M. Baranes"'
Publikováno v:
The Journal of Clinical Ethics. 31:126-135
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2771e789104f978be2acf0e2aaeb75c6
https://doi.org/10.1086/jce2020312126
https://doi.org/10.1086/jce2020312126
Publikováno v:
The Journal of clinical ethics. 31(2)
Dementia is a growing issue at the end of life that presents unique challenges for advance care planning. Advance directives are a useful and important component of end-of-life planning, but standard advance directives have less utility in cases of l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9797d0033750602aee03354570711550
https://pubmed.ncbi.nlm.nih.gov/32585656
https://pubmed.ncbi.nlm.nih.gov/32585656
Autor:
W. Marston Linehan, Christopher J. Ricketts, Darmood Wei, Sarah M. Baranes, Len Neckers, Pei-Jyun Liao, Carole Sourbier, Lernik Ohanjanian, L. Spencer Krane, Ming-Hui Wei, Cathy D. Vocke, Paul S. Meltzer, Youfeng Yang, J. Keith Killian, Deborah Citrin, Toshiki Kijima, Bradley T. Scroggins, Benjamin K. Gibbs
Publikováno v:
Oncotarget. 9:10723-10733
Papillary renal cell carcinomas (PRCC) are a histologically and genetically heterogeneous group of tumors that represent 15-20% of all kidney neoplasms and may require diverse therapeutic approaches. Alteration of the NF2 tumor suppressor gene, encod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5bdc37cc699145c6a38d05216fcf410
https://doi.org/10.18632/oncotarget.24112
https://doi.org/10.18632/oncotarget.24112
Autor:
Carole, Sourbier, Pei-Jyun, Liao, Christopher J, Ricketts, Darmood, Wei, Youfeng, Yang, Sarah M, Baranes, Benjamin K, Gibbs, Lernik, Ohanjanian, L, Spencer Krane, Bradley T, Scroggins, J, Keith Killian, Ming-Hui, Wei, Toshiki, Kijima, Paul S, Meltzer, Deborah E, Citrin, Len, Neckers, Cathy D, Vocke, W, Marston Linehan
Publikováno v:
Oncotarget
Papillary renal cell carcinomas (PRCC) are a histologically and genetically heterogeneous group of tumors that represent 15–20% of all kidney neoplasms and may require diverse therapeutic approaches. Alteration of the NF2 tumor suppressor gene, enc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::320733572a55fb0fa0e00ffc6e13602d
https://pubmed.ncbi.nlm.nih.gov/29535838
https://pubmed.ncbi.nlm.nih.gov/29535838
Autor:
Toshiki Kijima, Carole Sourbier, Lernik Ohanjanian, Penny Liao, Youfeng Yang, Len Neckers, W. Marston Linehan, Myriem Boufraqech, Cathy D. Vocke, Christopher J. Ricketts, Louis S. Krane, Ben Gibbs, Ming-Hui Wei, Sarah M. Baranes, Darmood Wei
Publikováno v:
Cancer Research. 76:1288-1288
About 10% of papillary renal cell carcinomas (PRCC) bear mutations in NF2 or SAV1, two members of the Hippo pathway, which controls cell growth by regulating the transcriptional activity of YES1-Associated Protein YAP1. NF2 or SAV1 mutations lead to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::404ad00e7f1b8ae0dab9a57567041049
https://doi.org/10.1158/1538-7445.am2016-1288
https://doi.org/10.1158/1538-7445.am2016-1288